{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3070,"total_is_capped":false,"direct_labels_cover":8,"predictions_cover":3070,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"f9f3e23ffbb1","filters":{"topic":"Bladder and Urothelial Cancer Treatments"}},"results":[{"id":"W2289712604","doi":"10.1016/s0140-6736(16)00561-4","title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3714,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; Genentech","keywords":"Atezolizumab; Metastatic Urothelial Carcinoma; Medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Population; Chemotherapy; Cancer; Progressive disease; Cohort; Urology; Immunotherapy; Bladder cancer; Pembrolizumab; Urothelial carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.02430309705466145,"gpt":0.2865667378326373,"spread":0.2622636407779759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008889219,0.0003528716,0.0007800146,0.00007022296,0.00007928454,0.00003382781,0.0001003353,0.00004286881,0.00003629658],"category_scores_gemma":[0.00002089994,0.0001510254,0.00007364742,0.0001305403,0.000124985,0.0001039124,0.00001183193,0.00008448296,0.000003211684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002633846,"about_ca_system_score_gemma":0.0002213459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001056625,"about_ca_topic_score_gemma":0.0001872827,"domain_scores_codex":[0.9983903,0.0000990214,0.0002680722,0.0004079024,0.0003659289,0.0004688152],"domain_scores_gemma":[0.9990952,0.0001288982,0.0001382217,0.0004525174,0.00005567667,0.0001294592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6098855,0.006217946,0.2146934,0.00007305997,0.0006964896,0.0002671737,0.001313439,0.000009771544,0.0005700608,0.000006338802,0.00004417595,0.1662227],"study_design_scores_gemma":[0.9232555,0.03697826,0.03127707,0.0006985365,0.0005759877,0.000008223214,0.00009140423,0.0002012647,0.005894478,0.00002402393,0.0006903118,0.000304924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994328,0.0002038247,0.0001694736,0.001070451,0.00004856945,0.003715705,0.0001222963,0.00005391741,0.0002877459],"genre_scores_gemma":[0.997496,0.0000143838,0.001250212,0.0004586745,0.000149737,0.0003655028,0.00002979736,0.00006330943,0.0001723877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.31337,"threshold_uncertainty_score":0.6158636,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2588916311","doi":"10.1056/nejmoa1613683","title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3390,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Cilag; Astellas Pharma; Sanofi; Exelixis; Eisai; BioClinica; Takeda Oncology; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Docetaxel; Chemotherapy; Oncology; Population; Gastroenterology; Urology; Cancer; Confidence interval; Surgery; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03598082071968254,"gpt":0.340225763948257,"spread":0.3042449432285744,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003993195,0.0002266536,0.0007097279,0.0001305289,0.0001986353,0.00002281964,0.00025946,0.00008281365,0.001033872],"category_scores_gemma":[0.0004218985,0.0001371768,0.0001838019,0.00003743987,0.0001351828,0.0001599531,0.00001700674,0.0002696252,0.00000814261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006668705,"about_ca_system_score_gemma":0.0005855293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001300462,"about_ca_topic_score_gemma":0.00003265554,"domain_scores_codex":[0.998579,0.0000317266,0.0005041458,0.0001842098,0.0004302015,0.0002707145],"domain_scores_gemma":[0.9981565,0.0001202447,0.0005262593,0.0004292607,0.0003329502,0.0004348175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05518001,0.0003133852,0.01783107,0.0001124626,0.0006309718,0.0006933744,0.001686981,0.000004306926,0.03360784,0.0002865399,0.01552348,0.8741296],"study_design_scores_gemma":[0.5207601,0.02914508,0.05026689,0.0005136797,0.0005374528,0.003778542,0.0001393046,0.00002277712,0.02689056,0.003691496,0.3640175,0.0002367209],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9655408,0.00451089,0.0004761823,0.01810245,0.001828968,0.0006260797,0.00001824783,0.00001571608,0.008880679],"genre_scores_gemma":[0.9799058,0.0008723125,0.0005526911,0.001751762,0.01077238,0.000008777483,0.000007904268,0.00004058398,0.006087802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8738928,"threshold_uncertainty_score":0.9998793,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2068523052","doi":"10.1038/nature12965","title":"Comprehensive molecular characterization of urothelial bladder carcinoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3055,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Joseph’s Healthcare Hamilton; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; National Center for Advancing Translational Sciences; National Cancer Institute; National Human Genome Research Institute; Massachusetts Institute of Technology; Dan L. Duncan Cancer Center, Baylor College of Medicine; School of Medicine, Indiana University; University of California, San Diego; National Heart, Lung, and Blood Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Brigham and Women's Hospital; University of North Carolina at Chapel Hill; Broad Institute; National Institute of Dental and Craniofacial Research; Research Institute, Nationwide Children's Hospital; Memorial Sloan-Kettering Cancer Center; University of Texas Southwestern Medical Center; Cleveland Clinic Foundation; Cleveland Clinic; University of Chicago; Harvard University; University of Pittsburgh; Nationwide Children's Hospital; SRA International; University of Miami","keywords":"Cancer research; Biology; microRNA; Chromatin; Gene; Targeted therapy; PI3K/AKT/mTOR pathway; Cancer; Genetics; Signal transduction","retraction":null,"screen_n_in":null,"score":{"opus":0.00806371073911861,"gpt":0.2592501045782343,"spread":0.2511863938391157,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002312986,0.0001084787,0.0002011091,0.0000547054,0.00002090659,0.000004573175,0.00005104812,0.0004269962,0.000127062],"category_scores_gemma":[0.00001766102,0.00008800338,0.00007611584,0.0001009815,0.00003300542,0.00003115485,0.00001502233,0.0004416796,0.00001876417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001931457,"about_ca_system_score_gemma":0.00004662741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001228524,"about_ca_topic_score_gemma":4.453436e-7,"domain_scores_codex":[0.9993647,0.00002888466,0.0001208404,0.000160798,0.0002086373,0.0001161632],"domain_scores_gemma":[0.9995022,0.00001194614,0.00005393268,0.0002123383,0.0001579748,0.0000616538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002567699,0.0001174022,0.01374319,0.00009871124,0.0001085933,0.00001848852,0.000173131,8.893136e-7,0.9793649,0.0008190618,0.0002448562,0.005053971],"study_design_scores_gemma":[0.003029271,0.0004881028,0.4802413,0.00004962101,0.0001924086,0.00003474018,0.00001288407,0.0001111556,0.4827509,0.0001538254,0.03280366,0.0001321411],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942717,0.0002574367,0.0003285589,0.000686461,0.0002342743,0.0002754359,0.00003742033,0.00002955354,0.00387916],"genre_scores_gemma":[0.9966241,0.00001198169,0.0002035678,0.002454719,0.0001984377,0.000008778554,0.0001051519,0.0000208559,0.0003723841],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.496614,"threshold_uncertainty_score":0.3588674,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2763670669","doi":"10.1016/j.cell.2017.09.007","title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","year":2017,"lang":"en","type":"article","venue":"Cell","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2495,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Cancer Institute; Universidade Estadual de Campinas; Pró-Reitoria de Pesquisa, Universidade Federal do Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Baylor College of Medicine; Leukemia and Lymphoma Society; U.S. Department of Defense; National Center for Advancing Translational Sciences; National Human Genome Research Institute; Michael and Susan Dell Foundation; AstraZeneca; Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas; Mary K. Chapman Foundation; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Biology; Bladder cancer; Cancer; Computational biology; Cancer research; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02539257569863974,"gpt":0.2933327346288253,"spread":0.2679401589301856,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001160576,0.00009580702,0.0001890035,0.00002793595,0.00007207357,0.00001278431,0.0000824713,0.00005079001,0.0003146472],"category_scores_gemma":[0.000008421835,0.00008293393,0.00006654947,0.00002306531,0.00006858107,0.00005759663,0.00003122342,0.00005312413,0.00003079019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002655446,"about_ca_system_score_gemma":0.0001078483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001939566,"about_ca_topic_score_gemma":0.000005796996,"domain_scores_codex":[0.9994829,0.00001058953,0.0001128971,0.0001527526,0.0001249083,0.0001159024],"domain_scores_gemma":[0.9992646,0.000008058806,0.0001358987,0.0003840219,0.0001417003,0.00006574576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00004807499,0.00009720843,0.005383394,0.0001250014,0.00007417178,0.0000372966,0.0002425658,0.000001076424,0.9909545,0.00001000304,0.00008993779,0.002936812],"study_design_scores_gemma":[0.00136883,0.0001123471,0.254216,0.00006779114,0.0001397839,0.000001977321,0.00002121737,0.00001040609,0.7400888,0.0000216853,0.003884334,0.00006674646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989035,0.0002757673,0.00007927593,0.0003691214,0.0002224425,0.000279787,0.00005192422,0.00001437359,0.009672344],"genre_scores_gemma":[0.9974199,0.0003545213,0.00007265241,0.0004668239,0.00009766733,0.00002528979,0.00004012142,0.0000187158,0.001504327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2508656,"threshold_uncertainty_score":0.3445166,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2559804019","doi":"10.1016/s0140-6736(16)32455-2","title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2211,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; Ipsen; Astellas Pharma; F. Hoffmann-La Roche; Eisai; Sanofi; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Atezolizumab; Medicine; Metastatic Urothelial Carcinoma; Clinical endpoint; Oncology; Internal medicine; Cisplatin; Chemotherapy; Progression-free survival; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Cancer; Bladder cancer; Urology; Clinical trial; Urothelial carcinoma; Immunotherapy; Pembrolizumab","retraction":null,"screen_n_in":null,"score":{"opus":0.03479870827848872,"gpt":0.3052424545209158,"spread":0.2704437462424271,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008508254,0.0003072448,0.0006905791,0.00007532709,0.00008374831,0.00002345116,0.00010521,0.00004303681,0.0001178656],"category_scores_gemma":[0.00007685296,0.0001378869,0.00006208517,0.0001565601,0.0001099257,0.0001037617,0.00003092114,0.0000834988,0.00004108617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000250514,"about_ca_system_score_gemma":0.0001553588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004416845,"about_ca_topic_score_gemma":0.0004901179,"domain_scores_codex":[0.9984878,0.00007628382,0.0003215105,0.0003774567,0.0002907457,0.0004462225],"domain_scores_gemma":[0.9990206,0.0001824061,0.000117715,0.0004617427,0.00006960025,0.0001479417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7106431,0.01367777,0.07628395,0.0001524258,0.0006392344,0.0004899074,0.00215727,0.00003321822,0.0009845643,0.0001188728,0.0003116699,0.194508],"study_design_scores_gemma":[0.9469596,0.02806273,0.01453808,0.0003692356,0.0006390527,0.0000425603,0.0000675667,0.00008823645,0.003772002,0.000346343,0.004795091,0.0003194848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935324,0.0003385424,0.00008267992,0.00200789,0.0001263179,0.002611797,0.0001905439,0.00004913047,0.001060739],"genre_scores_gemma":[0.997759,0.000207158,0.0004337564,0.0003812052,0.0003103759,0.0002586147,0.00003479283,0.00004208809,0.0005730279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2363165,"threshold_uncertainty_score":0.5622866,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162130153","doi":"10.1016/j.eururo.2012.07.033","title":"Epidemiology and Risk Factors of Urothelial Bladder Cancer","year":2012,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2187,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Medicine; Epidemiology; Incidence (geometry); Risk factor; Disease; Bladder cancer; Cancer; Genetic predisposition; Malignancy; Environmental health; Internal medicine; Gynecology","retraction":null,"screen_n_in":null,"score":{"opus":0.1107426596554793,"gpt":0.3733556826373355,"spread":0.2626130229818562,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006228058,0.0005281942,0.002701691,0.0002017141,0.00005831893,0.000001883691,0.0001675565,0.0003100619,0.0007997957],"category_scores_gemma":[0.0002705457,0.0003533897,0.0004439976,0.0001228684,0.0003715314,0.00002850291,0.0001461305,0.0006528819,0.0001725495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004660506,"about_ca_system_score_gemma":0.0001844312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003511742,"about_ca_topic_score_gemma":0.00001356878,"domain_scores_codex":[0.9960065,0.001956318,0.000843421,0.0005487619,0.00009883696,0.0005461659],"domain_scores_gemma":[0.9978179,0.0006545225,0.0006901147,0.0005040463,0.00004716702,0.0002862677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008614134,0.0001514263,0.03477233,0.002902096,0.002261571,0.00004308092,0.0001945288,3.795338e-7,6.574381e-7,0.0001017238,0.0006687547,0.9588173],"study_design_scores_gemma":[0.0006658593,0.0005873602,0.01072349,0.0003369898,0.01018891,0.0001560835,0.000004118093,5.191037e-7,9.707328e-7,0.00001728883,0.9770913,0.0002270964],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005014281,0.9902901,0.00002320738,0.00004738738,0.0006893605,0.0006836279,0.0004182755,0.0000490242,0.007297582],"genre_scores_gemma":[0.001354546,0.9962041,0.00008217635,0.0002689374,0.00090782,0.00003470973,0.00009381623,0.0001511554,0.0009026935],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9764225,"threshold_uncertainty_score":0.9998918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2103257412","doi":"10.1200/jco.2005.07.757","title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Transitional cell carcinoma; Hazard ratio; Cisplatin; Bladder cancer; Urology; Oncology; Methotrexate; Chemotherapy; Doxorubicin; Antimetabolite; Progression-free survival; Gastroenterology; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.08192046514609955,"gpt":0.4237490158951968,"spread":0.3418285507490972,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004316886,0.0003890793,0.00563351,0.0003206978,0.00004250218,0.00001357036,0.0002313663,0.0003756412,0.0002105778],"category_scores_gemma":[0.002430305,0.0002222455,0.0005373771,0.0003856854,0.0004534547,0.0002092658,0.00006353101,0.001188515,0.0000045269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005033835,"about_ca_system_score_gemma":0.002956778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003635754,"about_ca_topic_score_gemma":0.002537508,"domain_scores_codex":[0.9920939,0.001127596,0.004894588,0.0004206659,0.001006627,0.0004566649],"domain_scores_gemma":[0.9899384,0.004171566,0.00410124,0.0003219161,0.001041457,0.0004254585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7947931,0.002356828,0.1873783,0.0000416278,0.001754045,0.0001856618,0.0002303236,0.001262169,0.00001165468,0.000006929673,0.0002010419,0.01177836],"study_design_scores_gemma":[0.6875517,0.01718376,0.2923592,0.0004934956,0.001622022,0.00003062429,0.00002344525,0.0003322453,0.00006628237,0.000006639565,0.0001698765,0.000160711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922132,0.0002857507,0.0003386549,0.001348793,0.000882586,0.001706581,0.00002692611,0.00001323197,0.0031842],"genre_scores_gemma":[0.9925693,0.0002221709,0.004952338,0.000374902,0.001312104,0.00004174825,0.00002110941,0.00004879211,0.0004575963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1072414,"threshold_uncertainty_score":0.9062907,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2058331779","doi":"10.1016/j.juro.2016.10.101","title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","year":2016,"lang":"en","type":"article","venue":"The Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1537,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Bacillus (shape); Bladder tumor; Urinary bladder; Urology; Surgery; Pathology; Internal medicine; Bladder cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02106590330536847,"gpt":0.2788720960361228,"spread":0.2578061927307543,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003685287,0.0001201961,0.0003541209,0.0001001722,0.00002950739,0.00000173855,0.0001641568,0.00006166575,0.0002332117],"category_scores_gemma":[0.0000404269,0.00004231963,0.0001208525,0.0001067331,0.0001851739,0.00003887368,0.00001007122,0.0001284839,0.00001263627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007523381,"about_ca_system_score_gemma":0.0001364605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001508725,"about_ca_topic_score_gemma":0.00007985366,"domain_scores_codex":[0.9988564,0.0002687299,0.0004002075,0.00007272624,0.0002049135,0.0001970678],"domain_scores_gemma":[0.9991775,0.0003466436,0.0001469378,0.000215577,0.00006373777,0.00004965175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03588277,0.009084568,0.182894,0.00005594295,0.003182417,0.004094992,0.03407281,0.0001249282,0.1131507,0.0008513988,0.00629536,0.6103101],"study_design_scores_gemma":[0.03701996,0.07440056,0.768549,0.0001340652,0.003189746,0.01402108,0.002401401,0.00002703941,0.02720666,0.003877742,0.06879625,0.000376542],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823421,0.00179361,0.00006957162,0.01492176,0.0001888632,0.0001984317,0.00001116701,0.000002757492,0.0004717851],"genre_scores_gemma":[0.9974015,0.001151298,0.00003788489,0.0009061574,0.0003920813,0.000004457547,5.907358e-7,0.00001068315,0.00009531162],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6099336,"threshold_uncertainty_score":0.2553504,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3087464965","doi":"10.1056/nejmoa2002788","title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1479,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Foundation Medicine; Pharmacyclics; Novartis Pharma; EMD Serono; Genentech; LEO Pharma; Bavarian Nordic; Ipsen; Janssen Pharmaceuticals; AstraZeneca Australia; Astellas Pharma; Eisai; Bayer HealthCare; GlaxoSmithKline; UroGen Pharma; Takeda Oncology; Mirati Therapeutics; University of Patras; Clovis Oncology; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Janssen Biotech; Les Laboratories Pierre Fabre; Massachusetts Medical Society; Advanced Accelerator Applications; Merck KGaA; Endocyte; Pfizer; Incyte; Progenics Pharmaceuticals; Genesis Pharma; Yale University; Exelixis; Sanofi; Amgen; Heron Therapeutics; EUSA Pharma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Avelumab; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Medicine; Internal medicine; Carcinoma; Standard of care; Immunotherapy; Cancer; Bladder cancer; Pembrolizumab","retraction":null,"screen_n_in":null,"score":{"opus":0.05678166625801688,"gpt":0.3231609399121029,"spread":0.266379273654086,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002793559,0.0002081744,0.0007463633,0.00008229515,0.00004575765,0.000006914679,0.0001327878,0.00003628918,0.0005525155],"category_scores_gemma":[0.0005427866,0.0001082527,0.0001475057,0.0001696656,0.00007315342,0.0000846793,0.000008816451,0.0002285749,0.000005200318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005510629,"about_ca_system_score_gemma":0.0006208302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003666545,"about_ca_topic_score_gemma":0.000007789528,"domain_scores_codex":[0.9985529,0.00004848782,0.0005510308,0.0001779046,0.0004169732,0.0002527565],"domain_scores_gemma":[0.9985788,0.0002056861,0.0002830114,0.0001350422,0.0002667824,0.0005306793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.110401,0.0002983147,0.004532742,0.000266508,0.0009351749,0.001510256,0.006178703,0.00002965889,0.0238646,0.0001810876,0.05089331,0.8009086],"study_design_scores_gemma":[0.5450563,0.04678452,0.004187274,0.0005997341,0.0009344667,0.00282479,0.0007509501,0.0001712611,0.009973944,0.0009425294,0.3875171,0.0002571406],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7526677,0.0136531,0.03539826,0.1899822,0.002414232,0.00291692,0.00007637771,0.00007584476,0.002815447],"genre_scores_gemma":[0.9786221,0.0008715109,0.004479369,0.00917345,0.005607944,0.00001154016,0.000007252479,0.00004199547,0.001184855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8006515,"threshold_uncertainty_score":0.6049657,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4211115520","doi":"10.1016/s0140-6736(16)30512-8","title":"Bladder cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1453,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Bladder cancer; Cystectomy; Chemotherapy; Immunotherapy; Cisplatin; Disease; Cancer; Oncology; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1101377578314769,"gpt":0.4052873629048735,"spread":0.2951496050733966,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001013517,0.0002821697,0.001748256,0.00003651992,0.00005626242,0.00001641226,0.0002686672,0.0001428104,0.002126113],"category_scores_gemma":[0.00001586763,0.0001088092,0.0003355042,0.0001162865,0.00007053307,0.00001900687,0.00005045941,0.0002586964,0.001186564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001304696,"about_ca_system_score_gemma":0.0003907385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004996367,"about_ca_topic_score_gemma":0.000008393344,"domain_scores_codex":[0.9989578,0.00006715971,0.0002209127,0.0002476852,0.0001872237,0.0003192423],"domain_scores_gemma":[0.9988886,0.0000759802,0.0001159746,0.000815888,0.00002868375,0.00007488883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002081776,0.00001611172,0.0000121367,0.00257676,0.0006249089,0.0000148823,0.00001842599,3.280253e-9,1.302234e-7,0.00008641038,0.1046824,0.891947],"study_design_scores_gemma":[0.0007799747,0.00004095248,0.00002471958,0.01248542,0.001888332,0.00006303424,0.000001324927,5.211799e-8,0.000001262122,0.00008121831,0.9845005,0.0001332523],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[4.795182e-7,0.9684138,0.000003996654,0.001938686,0.0004431041,0.0006912703,0.0003075708,0.00007212356,0.02812901],"genre_scores_gemma":[0.000002622719,0.9747666,0.00002091398,0.001140975,0.006027838,0.0003771735,0.00002618061,0.00006178633,0.01757588],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8918138,"threshold_uncertainty_score":0.9995911,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2975497362","doi":"10.1016/j.eururo.2019.09.006","title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1360,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of Toronto; University Health Network; Mount Sinai Hospital; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Human Genome Research Institute; Novo Nordisk Fonden; Cancerfonden","keywords":"Medicine; Bladder cancer; Clinical trial; Disease; Bioinformatics; Computational biology; Oncology; Internal medicine; Cancer; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02201407623080887,"gpt":0.280815197036909,"spread":0.2588011208061001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008789488,0.0001178319,0.0002265529,0.00007085686,0.00001550387,0.000002790517,0.00007438647,0.0000463076,0.0008087003],"category_scores_gemma":[0.00004588658,0.0001019836,0.00007819097,0.00009683522,0.00009269811,0.00001169544,0.00003035404,0.0001141058,0.0005130194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002603197,"about_ca_system_score_gemma":0.0001252575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004946866,"about_ca_topic_score_gemma":0.000008447407,"domain_scores_codex":[0.9990623,0.0001634889,0.0002092193,0.0002664224,0.0001195953,0.0001789773],"domain_scores_gemma":[0.9993189,0.00005742065,0.0001054918,0.0003408399,0.0001039758,0.00007334693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0007524827,0.0003686028,0.09786865,0.0001286748,0.0006563002,0.0004553102,0.0007861467,0.00006997757,0.8785426,0.001664319,0.003614589,0.01509235],"study_design_scores_gemma":[0.004995829,0.001689138,0.9413806,0.00003937604,0.000477837,0.0001039992,0.0001184524,0.00009971888,0.0192185,0.000106097,0.0315642,0.0002062029],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9022064,0.0006806442,0.0000396698,0.001696442,0.000237778,0.0003376396,0.00002043132,0.00003880691,0.09474218],"genre_scores_gemma":[0.9964496,0.00006580104,0.000111224,0.002086075,0.0000782611,0.000009726361,0.00001684604,0.00003868592,0.001143759],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8593241,"threshold_uncertainty_score":0.8854702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2892569486","doi":"10.1016/j.eururo.2018.09.001","title":"Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018","year":2018,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":840,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Institute for Health and Care Research; World Health Organization","keywords":"Medicine; Epidemiology; Bladder cancer; Population; Environmental health; Risk factor; MEDLINE; Systematic review; Incidence (geometry); Disease; Cancer; Demography; Gerontology; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08891836199494443,"gpt":0.3647492421572954,"spread":0.2758308801623509,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001454788,0.0004577107,0.007033738,0.0002574562,0.00001827607,6.907414e-7,0.0002269429,0.0001987758,0.0001854088],"category_scores_gemma":[0.001128386,0.0002932686,0.0003962284,0.0002285988,0.0004077668,0.00002539369,0.0001301507,0.0003898051,0.00007064636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004470963,"about_ca_system_score_gemma":0.0002745755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003321059,"about_ca_topic_score_gemma":0.00002144933,"domain_scores_codex":[0.9929042,0.004092132,0.002099148,0.0005271871,0.000093933,0.0002833979],"domain_scores_gemma":[0.9963233,0.0008563509,0.001923377,0.0006929389,0.00008232366,0.0001216785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00004811473,0.0001184304,0.007567425,0.9839785,0.001819019,0.00006434486,0.0001144803,6.994573e-8,5.678909e-8,0.00002556577,0.00338115,0.002882851],"study_design_scores_gemma":[0.002355036,0.002331721,0.005058743,0.5622261,0.04600079,0.0002777197,0.00002156457,0.000001956036,0.000001105947,0.000058297,0.3810152,0.0006517229],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008083455,0.9952965,0.000004376513,0.00006385946,0.0001859246,0.002234232,0.0004206025,0.00001751644,0.001696171],"genre_scores_gemma":[0.001577768,0.9972553,0.00003031507,0.0006692475,0.00008316794,0.00006929781,0.0001093964,0.00008144873,0.0001240751],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4217524,"threshold_uncertainty_score":0.999952,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2604535399","doi":"10.1016/j.eururo.2017.03.030","title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","year":2017,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":792,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; Genome British Columbia; University of British Columbia","funders":"National Cancer Institute","keywords":"Subtyping; Medicine; Bladder cancer; Concordance; Oncology; Proportional hazards model; Internal medicine; Hazard ratio; Surgical oncology; Context (archaeology); Cancer; Confidence interval; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0161125259594105,"gpt":0.3102048239537633,"spread":0.2940922979943528,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002834296,0.0001727689,0.0003046775,0.0001000018,0.0000501204,0.00001361124,0.0001067616,0.00005495331,0.0001803747],"category_scores_gemma":[0.0002080957,0.0001340611,0.00008513006,0.00003579228,0.0001648934,0.00004169507,0.00005555755,0.0001693065,0.00001270023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004545351,"about_ca_system_score_gemma":0.0001052442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003989136,"about_ca_topic_score_gemma":0.0001189101,"domain_scores_codex":[0.9988329,0.0003036864,0.0001935398,0.0003071191,0.0001169761,0.0002458061],"domain_scores_gemma":[0.9991834,0.0001032017,0.0001238884,0.0004485726,0.00004572299,0.00009519245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01684047,0.0002129583,0.9342785,0.00001981527,0.0003084777,0.001370556,0.001380599,0.00003881127,0.02971236,0.000006099725,0.00003893901,0.01579243],"study_design_scores_gemma":[0.00423003,0.002415454,0.9911926,0.00004563449,0.00006984334,0.00002114437,0.0000152741,0.00001913477,0.001679801,0.00001927857,0.000197137,0.00009471204],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937266,0.0007050905,0.000008553063,0.001005158,0.0001267422,0.0002366286,0.00002759477,0.00001743098,0.004146243],"genre_scores_gemma":[0.998743,0.0002524493,0.00002078593,0.0006887685,0.0001064243,0.00001240221,0.000002656019,0.00004838789,0.0001251011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05691407,"threshold_uncertainty_score":0.5466852,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152455106","doi":"10.1016/j.eururo.2009.06.028","title":"Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy","year":2009,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":760,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Carcinoma in situ; Cystoscopy; Epidemiology; Disease; Stage (stratigraphy); Oncology; Internal medicine; Urology; Cancer; Urinary system","retraction":null,"screen_n_in":null,"score":{"opus":0.08428718980636966,"gpt":0.4003877663653995,"spread":0.3161005765590298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002431692,0.0005316893,0.002304421,0.0002485759,0.00003369982,0.000004646457,0.0001659948,0.0001737055,0.0001186658],"category_scores_gemma":[0.0002030786,0.000369627,0.0002347793,0.0002091518,0.0001399944,0.00002591039,0.0000945165,0.0002948943,0.00006610254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000157701,"about_ca_system_score_gemma":0.000564086,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004265018,"about_ca_topic_score_gemma":0.0001327417,"domain_scores_codex":[0.9965075,0.001160533,0.0008390981,0.0009065885,0.0001015262,0.0004847826],"domain_scores_gemma":[0.9981526,0.0004673187,0.0003743063,0.0005254538,0.00004614955,0.0004341914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002936481,0.0003103691,0.00261877,0.0008116204,0.0002196052,0.00051809,0.0001294923,0.000005623934,0.000001619902,0.00001092683,0.0002218635,0.9948584],"study_design_scores_gemma":[0.002839861,0.009380648,0.1065762,0.009484064,0.003873988,0.00003328402,0.00001094329,0.000006779561,0.000003163984,0.0001388128,0.867124,0.0005282907],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002614693,0.9931884,0.000009341431,0.0004141582,0.0001873561,0.00180808,0.0004013676,0.00002446415,0.001352134],"genre_scores_gemma":[0.008456618,0.9897869,0.0001646376,0.0005795264,0.0003256015,0.0001856374,0.0002894306,0.00006570969,0.0001459385],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9943301,"threshold_uncertainty_score":0.9998755,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1271572098","doi":"10.1016/j.eururo.2015.08.037","title":"Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes","year":2015,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":683,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Medicine; Bladder cancer; Cancer; Incidence (geometry); Oncology; Internal medicine; Disease; Gynecology","retraction":null,"screen_n_in":null,"score":{"opus":0.07411168531003823,"gpt":0.4086785324755147,"spread":0.3345668471654765,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005035968,0.0004410468,0.002781915,0.0001431718,0.00003423867,0.000004170974,0.0001159279,0.0002138529,0.0001729036],"category_scores_gemma":[0.0001787039,0.0002866722,0.0001573138,0.0001964263,0.0005437047,0.00002068492,0.0001819585,0.0003429947,0.00003662504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000385946,"about_ca_system_score_gemma":0.0005437238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002401221,"about_ca_topic_score_gemma":0.000003814111,"domain_scores_codex":[0.997334,0.001136703,0.0006215072,0.0005579368,0.00008513487,0.000264707],"domain_scores_gemma":[0.9986761,0.0001650819,0.0004052907,0.0003632155,0.0002046333,0.000185661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006334358,0.00009928257,0.002222438,0.04893946,0.002595191,0.000121968,0.0001820566,1.305684e-8,7.95179e-7,0.0004503451,0.01478298,0.9305421],"study_design_scores_gemma":[0.0009592255,0.0006994726,0.0009619382,0.004352849,0.004569185,0.0002755967,0.000009741682,9.910212e-8,1.073711e-7,0.00004081819,0.987938,0.0001928962],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001143805,0.9818406,0.000003110744,0.0004258212,0.0002245443,0.001174028,0.0004233174,0.00003088597,0.01586623],"genre_scores_gemma":[0.00004254617,0.9961357,0.0001196215,0.002926274,0.0001529603,0.00008255422,0.0001593473,0.00007025569,0.0003107686],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9731551,"threshold_uncertainty_score":0.9999585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3164197656","doi":"10.1016/s1470-2045(21)00152-2","title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":648,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; British Microcirculation Society; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; AstraZeneca; Bayer; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; LEO Pharma Research Foundation; Pfizer","keywords":"Medicine; Pembrolizumab; Carboplatin; Gemcitabine; Chemotherapy; Oncology; Internal medicine; Metastatic Urothelial Carcinoma; Urothelial carcinoma; Population; Cisplatin; Cancer; Immunotherapy; Bladder cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1011570383933493,"gpt":0.4104142656501243,"spread":0.309257227256775,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005811644,0.0005705614,0.002098113,0.00006897758,0.000369308,0.00008303918,0.0006212165,0.0002757229,0.001438344],"category_scores_gemma":[0.0001943128,0.0003299218,0.0002059412,0.0003972918,0.0002754608,0.0001316819,0.00007543431,0.0003863378,0.00003388621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003806034,"about_ca_system_score_gemma":0.002402783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001372857,"about_ca_topic_score_gemma":0.0003532231,"domain_scores_codex":[0.9970204,0.0003269806,0.0006293426,0.0007989886,0.0003891659,0.0008350844],"domain_scores_gemma":[0.9968762,0.00111261,0.0003487494,0.001091495,0.0003303677,0.0002406166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9276526,0.005803547,0.00003734816,0.00005685462,0.001287246,0.0002769305,0.0008339871,0.000005647238,0.003893799,0.0001607599,0.003990805,0.05600045],"study_design_scores_gemma":[0.7501925,0.08513039,0.00006577921,0.00004934283,0.0003466369,0.0002048166,0.0001166647,0.00009509153,0.02193521,0.0002919314,0.1412564,0.0003152646],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9331448,0.001136141,0.000426427,0.04724117,0.001221011,0.01184644,0.0001710134,0.0001579974,0.004654972],"genre_scores_gemma":[0.9462907,0.006003082,0.004664546,0.02766821,0.003895396,0.004209219,0.0003270334,0.0002662556,0.006675615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1774602,"threshold_uncertainty_score":0.9999153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3168935284","doi":"10.1038/s41586-021-03642-9","title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","year":2021,"lang":"en","type":"article","venue":"Nature","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"","keywords":"Hazard ratio; Medicine; Atezolizumab; Internal medicine; Confidence interval; Oncology; Population; Clinical endpoint; Adjuvant; Bladder cancer; Adjuvant therapy; Biomarker; Immunotherapy; Cancer; Randomized controlled trial; Nivolumab; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0179659904279273,"gpt":0.294829534070764,"spread":0.2768635436428367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006553739,0.0001390623,0.0002569826,0.00007049734,0.00003786571,0.00001487856,0.00006500214,0.000560376,0.0005851037],"category_scores_gemma":[0.00004121911,0.0001157001,0.0001010695,0.0002519818,0.00001820779,0.00004574938,0.00002156245,0.0007819328,0.00003597622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000131739,"about_ca_system_score_gemma":0.0002922631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008153452,"about_ca_topic_score_gemma":0.00004775873,"domain_scores_codex":[0.9990857,0.00003393913,0.0001610465,0.0002635789,0.0002280041,0.0002277508],"domain_scores_gemma":[0.9995224,0.00002083731,0.0000261092,0.0002850419,0.00007944242,0.00006609802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001859818,0.001055275,0.5510423,0.000178326,0.0003640082,0.00556065,0.002337756,0.000005088396,0.3210591,0.001623182,0.01573646,0.09917798],"study_design_scores_gemma":[0.01254966,0.0003344485,0.6325203,0.0002443051,0.00009077544,0.0004449544,0.0002873371,0.00003940212,0.2020785,0.0005687483,0.1505137,0.0003278838],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9426072,0.02755944,0.00001443237,0.003808284,0.0007409886,0.000307441,0.00003234047,0.00005674054,0.02487308],"genre_scores_gemma":[0.9912376,0.0002936136,0.0004526228,0.004802508,0.0003489322,0.00001873963,0.00003392335,0.00003057812,0.002781468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1347772,"threshold_uncertainty_score":0.6406475,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3164781831","doi":"10.1016/s1470-2045(21)00147-9","title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":533,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Pfizer Japan; Genentech; Bavarian Nordic; Merck Sharp and Dohme; Ono Pharmaceutical; European Association of Urology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Sanofi; GlaxoSmithKline; Merck; Genzyme; Genomic Health; Chugai Pharmaceutical; Roche; Astellas Pharma US; Pfizer; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Cystoscopy; Bladder cancer; Cystectomy; Cancer; Internal medicine; Clinical endpoint; Surgery; Progressive disease; Urology; Oncology; Clinical trial; Immunotherapy; Disease; Urinary system","retraction":null,"screen_n_in":null,"score":{"opus":0.1191642110718247,"gpt":0.4364849762544737,"spread":0.3173207651826491,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003211092,0.0003863735,0.001227535,0.00006992641,0.0003236888,0.00004941225,0.0005185082,0.0001335987,0.0003679892],"category_scores_gemma":[0.0001477278,0.0002166905,0.0001096897,0.0003290406,0.0001480589,0.00008540498,0.0001028502,0.0001760501,0.00001938928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007021311,"about_ca_system_score_gemma":0.001190643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005355675,"about_ca_topic_score_gemma":0.01083279,"domain_scores_codex":[0.997413,0.0006123316,0.0004641006,0.0006478565,0.000265525,0.0005971756],"domain_scores_gemma":[0.9963145,0.001525251,0.0002913601,0.001208396,0.00045515,0.0002052965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1147223,0.09657296,0.003440816,0.00007114328,0.007795713,0.0006400418,0.05264287,0.0004623357,0.03232995,0.0001742325,0.005419781,0.6857278],"study_design_scores_gemma":[0.4186711,0.3097703,0.03657388,0.0001593661,0.008200466,0.0001123541,0.01712411,0.0005340608,0.07832822,0.0007109439,0.1290085,0.0008066364],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795064,0.001823792,0.0003423057,0.009373995,0.0007428222,0.006996357,0.000711795,0.00004205373,0.0004604525],"genre_scores_gemma":[0.9851564,0.003672328,0.001667045,0.004390954,0.001134051,0.002714235,0.00005911144,0.00008251458,0.00112333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6849212,"threshold_uncertainty_score":0.8836381,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3087466624","doi":"10.1016/s1470-2045(20)30541-6","title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Foundation Medicine; EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Astellas Pharma; Eisai; INOVIO Pharmaceuticals; AstraZeneca España; Pfizer; Incyte; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Endocyte; Sanofi; Exelixis; GlaxoSmithKline; Celldex Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Tremelimumab; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Open label; Internal medicine; Urology; Carcinoma; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy; Bladder cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.09417910979039026,"gpt":0.3763797989152469,"spread":0.2822006891248566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005186896,0.0005252264,0.002032255,0.00009416519,0.0001653972,0.00007219124,0.000503529,0.0001449167,0.0003237716],"category_scores_gemma":[0.000424835,0.000307977,0.00007014356,0.00055918,0.000273793,0.0002039387,0.0001563044,0.0004565531,0.00002582885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005817219,"about_ca_system_score_gemma":0.001532187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007294038,"about_ca_topic_score_gemma":0.001467395,"domain_scores_codex":[0.9963966,0.0007890033,0.0007138422,0.0007811916,0.0004827287,0.0008366596],"domain_scores_gemma":[0.9979019,0.0006872502,0.000324076,0.0005491864,0.0001763628,0.000361244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9603977,0.003200248,0.001155982,0.0001357913,0.0007469211,0.0004199976,0.002624563,0.00003311913,0.0002087759,0.00001272337,0.0004553691,0.03060878],"study_design_scores_gemma":[0.9419318,0.04964035,0.001755336,0.0001134089,0.0009722415,0.00003358674,0.0002965972,0.001289783,0.0003219243,0.00001701613,0.003293934,0.0003339624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803576,0.0007159325,0.00006101171,0.004371427,0.0002791409,0.01245093,0.0001453621,0.00008938685,0.001529133],"genre_scores_gemma":[0.992108,0.000628259,0.001492399,0.003836087,0.0003951862,0.001029817,0.0001379339,0.0001037399,0.0002686076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04644011,"threshold_uncertainty_score":0.9999372,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2943108118","doi":"10.1093/annonc/mdz127","title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":488,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Cilag; National Center for Advancing Translational Sciences; National Cancer Institute; Foundation Medicine; Ipsen; EMD Serono; Sanofi; Fidia Farmaceutici; Eisai; Astellas Pharma; Merck Sharp and Dohme; Genentech; GlaxoSmithKline; UroGen Pharma; Pfizer; Incyte; Exelixis; Kidney Cancer Association; Merck; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; AstraZeneca; Amgen","keywords":"Medicine; Docetaxel; Urothelial cancer; Paclitaxel; Pembrolizumab; Oncology; Internal medicine; Cancer; Chemotherapy; Randomized controlled trial; Bladder cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.08149898714952458,"gpt":0.4267595225361745,"spread":0.3452605353866499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009126515,0.000253388,0.002710537,0.0003329496,0.00001175067,0.000001638136,0.0002098975,0.0002445354,0.0003924284],"category_scores_gemma":[0.001117848,0.0002035596,0.0004793855,0.0003866458,0.0003313766,0.00008801796,0.00006324868,0.0002040535,0.000004959696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009749288,"about_ca_system_score_gemma":0.001327079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001309488,"about_ca_topic_score_gemma":0.0003591557,"domain_scores_codex":[0.9966806,0.0003732154,0.001749213,0.0003776862,0.0004587008,0.0003606536],"domain_scores_gemma":[0.9966195,0.001049497,0.00124209,0.0005161678,0.0004492701,0.0001235013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9103345,0.002598484,0.00004440982,0.0002184637,0.0007177831,0.00002406379,0.0009663253,0.00002785824,0.008117405,0.0001107314,0.0006399567,0.07620005],"study_design_scores_gemma":[0.9180848,0.04180964,0.0001868891,0.0003874239,0.0004362988,0.000003482334,0.0001278052,0.00003450113,0.0306149,0.00009449785,0.008080275,0.0001394873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877571,0.001540226,0.000005579401,0.0007250923,0.001627723,0.002843498,0.0005644446,0.00001246792,0.004923911],"genre_scores_gemma":[0.9942096,0.004413344,0.0001790502,0.000101353,0.000139165,0.0001516778,0.00005211673,0.00002949214,0.0007242188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07606056,"threshold_uncertainty_score":0.8300921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4376645144","doi":"10.1016/j.eururo.2023.03.029","title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","year":2023,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":481,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"National Institute for Health and Care Research; World Health Organization","keywords":"Medicine; Epidemiology; Environmental health; Bladder cancer; Risk factor; Cancer; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1078419221677173,"gpt":0.3983216837672977,"spread":0.2904797615995803,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001790215,0.0004726266,0.007534608,0.0004089188,0.0000149341,4.744673e-7,0.0003160036,0.000216146,0.0005455018],"category_scores_gemma":[0.003486838,0.0003069189,0.0008417039,0.000611886,0.0001643754,0.0000144029,0.0001303617,0.0005766684,0.000346065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008754279,"about_ca_system_score_gemma":0.0003134235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004270193,"about_ca_topic_score_gemma":0.00004244093,"domain_scores_codex":[0.9917127,0.004640986,0.002580476,0.0005234346,0.0001583737,0.0003840518],"domain_scores_gemma":[0.9950667,0.002020024,0.001912867,0.0007998333,0.00009154371,0.0001090018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00001578093,0.00008050251,0.001580134,0.9900706,0.001423977,0.0001027011,0.0000638906,9.202943e-7,3.868377e-8,0.00002479422,0.00055903,0.006077597],"study_design_scores_gemma":[0.0007152068,0.0005057263,0.003230279,0.9233155,0.02109919,0.00008051265,0.00001395316,0.000001727321,2.137387e-7,0.00002647797,0.05071935,0.0002919262],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001525542,0.9947226,0.000004386349,0.00004135609,0.0003500934,0.002275938,0.0005824801,0.00003354287,0.001974347],"genre_scores_gemma":[0.00007428107,0.9984671,0.00001402403,0.0003177714,0.0001056181,0.000155408,0.000131032,0.0001294677,0.0006052289],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.06675519,"threshold_uncertainty_score":0.9999383,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3120445389","doi":"10.1016/j.eururo.2020.12.033","title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","year":2021,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bladder cancer; Grading (engineering); Proportional hazards model; Risk factor; Cystectomy; Concomitant; Internal medicine; Oncology; Carcinoma in situ; Clinical endpoint; Urology; Cancer; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.06401271365823098,"gpt":0.3034778241472664,"spread":0.2394651104890354,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001090114,0.0003353915,0.0005564073,0.00005893542,0.0003662095,0.00007058985,0.0002820144,0.0001335538,0.0000256367],"category_scores_gemma":[0.001969505,0.0002146265,0.0001486049,0.0001686227,0.0001739366,0.0001207677,0.0001064682,0.0003055664,0.00001663346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008137871,"about_ca_system_score_gemma":0.0002668107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005364874,"about_ca_topic_score_gemma":0.00063176,"domain_scores_codex":[0.9960289,0.001774676,0.000826798,0.0007029789,0.0002384724,0.0004281744],"domain_scores_gemma":[0.9957908,0.001608515,0.001010156,0.0006065107,0.0008589076,0.0001251065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002294601,0.001041667,0.771454,0.0005187294,0.00524641,0.00016396,0.01116174,0.000957228,0.0317038,0.001651075,0.08892422,0.08488251],"study_design_scores_gemma":[0.006265527,0.002137709,0.9295159,0.0001332749,0.002546886,0.00003886038,0.0009518487,0.008791386,0.0003434233,0.0005955556,0.04827842,0.0004012235],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9464526,0.01010784,0.01176148,0.0210179,0.001818924,0.004337985,0.003449979,0.0001403464,0.0009130024],"genre_scores_gemma":[0.9912383,0.001720631,0.0004058655,0.003313834,0.001901529,0.0002282433,0.0005911799,0.0001297596,0.0004706398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1580618,"threshold_uncertainty_score":0.8752214,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077936479","doi":"10.1016/j.eururo.2013.03.059","title":"Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data","year":2013,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":450,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Cystoscopy; Bladder cancer; Carcinoma in situ; Confidence interval; Odds ratio; Urology; Relative risk; Meta-analysis; Carcinoma; Prospective cohort study; Cancer; Internal medicine; Surgery; Urinary system","retraction":null,"screen_n_in":null,"score":{"opus":0.1176507442470511,"gpt":0.3583073433956708,"spread":0.2406565991486196,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003443226,0.0005641264,0.003861189,0.0007172428,0.00004375785,0.00001056007,0.0003942465,0.0001572406,0.0006008014],"category_scores_gemma":[0.0001066789,0.0003607323,0.0006345832,0.0008154623,0.000269416,0.00005800097,0.0001551416,0.0003913505,0.00002173447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000539356,"about_ca_system_score_gemma":0.0003060188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005839695,"about_ca_topic_score_gemma":0.0004282393,"domain_scores_codex":[0.9968039,0.000840688,0.0007521535,0.00102259,0.0002965256,0.0002841471],"domain_scores_gemma":[0.9966131,0.0005687601,0.0009425955,0.001566459,0.0001746184,0.0001344354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0003987754,0.0006411849,0.000335002,0.008077653,0.2222311,0.0002255624,0.000134771,0.0001539394,0.00005094582,0.000001830248,0.0001916074,0.7675577],"study_design_scores_gemma":[0.001477236,0.003765653,0.002839298,0.0009703294,0.9197581,0.00002820956,0.000008099067,0.0009350302,0.0001071669,8.804099e-7,0.06968186,0.0004281189],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0013574,0.9938762,0.0002662298,0.00007147532,0.0001159935,0.00172012,0.001498072,0.00002605805,0.001068418],"genre_scores_gemma":[0.07401942,0.9243301,0.0001654418,0.000315423,0.00005434153,0.0003839929,0.0005217536,0.0001065142,0.0001030502],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7671295,"threshold_uncertainty_score":0.9998845,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035660473","doi":"10.1002/cncr.22588","title":"PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":441,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"Richard M. Schulze Family Foundation; Commonwealth Foundation","keywords":"Medicine; Bladder cancer; Odds ratio; Oncology; Carcinoma; Immunohistochemistry; Stage (stratigraphy); Cohort; Tissue microarray; Internal medicine; Carcinoma in situ; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0186577435477403,"gpt":0.2914737862695429,"spread":0.2728160427218026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001023346,0.0001694456,0.0002497567,0.00003903084,0.00009037338,0.000008395428,0.0001099019,0.0001049735,0.0003656779],"category_scores_gemma":[0.00001780816,0.000105211,0.00008046369,0.0001329923,0.0001107867,0.00005536074,0.00004562245,0.000143013,0.000005367541],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007982114,"about_ca_system_score_gemma":0.0001282036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008414569,"about_ca_topic_score_gemma":0.00006600122,"domain_scores_codex":[0.9989462,0.00002516322,0.0002229176,0.0002602524,0.0002834477,0.0002620508],"domain_scores_gemma":[0.9993128,0.00003376757,0.00008750522,0.0003634674,0.00006653251,0.0001359793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001049441,0.0002076,0.1963734,0.0001496513,0.0001424486,0.00002118106,0.001260116,6.60727e-7,0.7531075,0.00004576744,0.02329308,0.02434912],"study_design_scores_gemma":[0.003304869,0.0001940505,0.239525,0.0001678634,0.0001720628,0.0000205543,0.0001421316,0.000006532638,0.7436759,0.00006561642,0.01258907,0.0001363252],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989938,0.003241796,0.00003382348,0.0005104453,0.0003906099,0.0004840895,0.0001100824,0.00002358488,0.005267569],"genre_scores_gemma":[0.9967148,0.0001404013,0.00003714452,0.000795329,0.0002849571,0.00003710018,0.000007491015,0.00003093455,0.001951859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04315155,"threshold_uncertainty_score":0.4290379,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128580887","doi":"10.1016/j.urology.2005.08.064","title":"Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers","year":2005,"lang":"en","type":"article","venue":"Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"National Cancer Institute","keywords":"Medicine; Bladder cancer; Tumor marker; Cytology; Urine cytology; Oncology; Prostate cancer; Bladder tumor; Urology; Cancer; Prospective cohort study; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.01920896340608052,"gpt":0.2761713243428109,"spread":0.2569623609367304,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001737522,0.0003494517,0.0004715336,0.0002554049,0.00009655677,0.00001625991,0.0002086875,0.0001737873,0.006397455],"category_scores_gemma":[0.0001512604,0.0003059195,0.0001748136,0.0001246614,0.0003661014,0.00004421554,0.00007176895,0.000430429,0.0011458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001841735,"about_ca_system_score_gemma":0.0002520153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007612689,"about_ca_topic_score_gemma":0.00007570208,"domain_scores_codex":[0.9979004,0.0001290299,0.000414876,0.0006338451,0.0003212579,0.0006005481],"domain_scores_gemma":[0.9988195,0.000238651,0.0001404051,0.0004346555,0.0001148337,0.000251964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04197156,0.003467322,0.07820737,0.00008059591,0.007520266,0.007716643,0.001046809,0.0004600695,0.005655611,0.003819298,0.7993349,0.05071953],"study_design_scores_gemma":[0.02096474,0.005237245,0.1121117,0.00003153963,0.00119512,0.005975092,0.0003932201,0.00230473,0.002354516,0.001147063,0.8474265,0.0008585174],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7120119,0.0005411507,0.00006718205,0.07059346,0.00234757,0.001004083,0.0001966374,0.0002688462,0.2129692],"genre_scores_gemma":[0.9569157,0.00003064227,0.0006940272,0.03656056,0.0007918849,0.00008560072,0.00008504717,0.00006238833,0.004774132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2449038,"threshold_uncertainty_score":0.9999393,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137616140","doi":"10.1016/s1470-2045(14)71160-x","title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":387,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Notre-Dame; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Eli Lilly and Company","keywords":"Cystectomy; Urothelial carcinoma; Medicine; Urology; Open label; Chemotherapy; Carcinoma; Oncology; Urothelial cancer; Bladder cancer; Randomized controlled trial; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05177285702388124,"gpt":0.3588977588261558,"spread":0.3071249018022745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007043824,0.0003116741,0.001167613,0.00007442013,0.00007714509,0.0000251263,0.0006603099,0.0001982934,0.0004220638],"category_scores_gemma":[0.0001495263,0.0001452316,0.00009387411,0.0002509815,0.0004292184,0.0001035829,0.0001264538,0.0003925225,0.00001215781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002067386,"about_ca_system_score_gemma":0.0005132952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002838046,"about_ca_topic_score_gemma":0.0006410227,"domain_scores_codex":[0.997358,0.0008421267,0.000537038,0.0004148756,0.0003544573,0.0004934687],"domain_scores_gemma":[0.9982937,0.0003710484,0.0002662121,0.0008302934,0.00008859095,0.0001501694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9707775,0.003497607,0.01213996,0.00002674074,0.0003329049,0.00002619785,0.001241759,8.938037e-7,0.0002394736,0.00002824967,0.0004742084,0.01121453],"study_design_scores_gemma":[0.922922,0.02568744,0.04271385,0.00006010232,0.0003561027,0.00001208361,0.0000602925,0.00007084658,0.000671204,0.00005146403,0.007209624,0.0001849856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912723,0.00005377618,0.00003066866,0.001630828,0.000939205,0.004245144,0.00007173719,0.00002606612,0.001730322],"genre_scores_gemma":[0.9954386,0.0000219829,0.0001806169,0.002479611,0.000940519,0.000688847,0.0000340089,0.00005636874,0.0001594257],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04785547,"threshold_uncertainty_score":0.5922371,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1982719862","doi":"10.1111/j.1464-410x.2009.09076.x","title":"The effect of age and gender on bladder cancer: a critical review of the literature","year":2009,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":368,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Referral; Disease; Epidemiology; Bladder cancer; Incidence (geometry); MEDLINE; Cancer; Gerontology; Family medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02755185034392202,"gpt":0.3560524491874857,"spread":0.3285005988435638,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005986677,0.0002415017,0.002069442,0.00005983926,0.00006650083,0.00001760519,0.0002348079,0.0002570236,0.00005621263],"category_scores_gemma":[0.0006823829,0.0001207998,0.0007606368,0.0001883348,0.0002944493,0.00002447964,0.00003724275,0.0009850319,6.8401e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003991256,"about_ca_system_score_gemma":0.000300937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001145955,"about_ca_topic_score_gemma":0.000005415834,"domain_scores_codex":[0.9976278,0.000823052,0.0008353255,0.000171206,0.0003327856,0.0002098436],"domain_scores_gemma":[0.9981544,0.0007048143,0.000588236,0.0002513218,0.0002015415,0.00009967382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000132222,0.00005707667,0.00001597684,0.04071916,0.0006270966,0.001071536,0.00001891063,4.383813e-8,4.490931e-7,0.00002891035,0.00714061,0.950188],"study_design_scores_gemma":[0.001087663,0.00302195,0.0005628217,0.1711218,0.007584458,0.02625695,9.478653e-7,7.227768e-8,0.000002948657,0.0001225936,0.7901438,0.0000940114],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004854586,0.9974003,8.15269e-7,0.000875177,0.0003870473,0.0006120093,0.00008593543,0.000002189682,0.0005880127],"genre_scores_gemma":[0.0005357712,0.9976878,0.00001013991,0.001261105,0.0003644435,0.0000185287,0.000004217859,0.00002476658,0.00009322848],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.950094,"threshold_uncertainty_score":0.4926072,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035062922","doi":"10.1016/j.eururo.2006.05.021","title":"Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy","year":2006,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Cystectomy; Medicine; Stage (stratigraphy); Bladder cancer; Lymphadenectomy; Carcinoma in situ; Transitional cell carcinoma; Surgery; Radical surgery; Carcinoma; Urology; Cancer; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02579578882443177,"gpt":0.3319970850088622,"spread":0.3062012961844304,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003416643,0.000218777,0.0004196086,0.00007236857,0.00004865128,0.00001560054,0.00007229935,0.0001000975,0.0002518597],"category_scores_gemma":[0.00006008782,0.000140675,0.0001595618,0.00007877657,0.0003217895,0.00002931694,0.00006764868,0.000342237,0.0002559627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001984676,"about_ca_system_score_gemma":0.00003665133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003730296,"about_ca_topic_score_gemma":0.000003160315,"domain_scores_codex":[0.9981211,0.000564675,0.0003745174,0.000471437,0.0001343188,0.000333982],"domain_scores_gemma":[0.9993061,0.0001336372,0.00007083307,0.0002820601,0.0000227848,0.0001845877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009536234,0.0002788555,0.9879341,0.00001253489,0.00008397271,0.002242642,0.00003040804,5.122267e-7,0.00001835804,0.00004513822,0.0007899353,0.007609975],"study_design_scores_gemma":[0.003222468,0.004492481,0.9759358,0.00001153858,0.0002125743,0.0001395466,0.000002755784,0.00000377117,0.00002586636,0.00008819659,0.0157453,0.0001197608],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792991,0.0005486304,0.00004754309,0.001166037,0.0001023564,0.0003832912,0.00006428293,0.000108979,0.01827979],"genre_scores_gemma":[0.9966124,0.00003697862,0.0002108325,0.001312782,0.0008802831,0.00002072473,0.00004065488,0.00004627126,0.0008390441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01744074,"threshold_uncertainty_score":0.5736558,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1895605570","doi":"10.1111/bju.12121","title":"Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes","year":2013,"lang":"en","type":"review","venue":"British Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":360,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Cystectomy; Urinary diversion; Medicine; Bladder cancer; Context (archaeology); Urinary system; Surgery; Stoma (medicine); General surgery; Urology; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0215026174737906,"gpt":0.3124257923146673,"spread":0.2909231748408767,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001089542,0.0002444483,0.001431873,0.0001930927,0.0000974207,0.00002938671,0.00007858058,0.0003235894,0.0004830231],"category_scores_gemma":[0.00005284293,0.0002016176,0.0004735973,0.00008478697,0.00008796667,0.00008794538,0.00004816823,0.0004617151,0.000007819481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001453437,"about_ca_system_score_gemma":0.0003971849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001050994,"about_ca_topic_score_gemma":0.00001297315,"domain_scores_codex":[0.9985237,0.0001401026,0.0006472744,0.0002427878,0.0001928209,0.0002533679],"domain_scores_gemma":[0.9989262,0.0001125287,0.0004234513,0.00008387328,0.0002409775,0.0002129673],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002096442,0.0002617,0.001003882,0.001799981,0.001198625,0.0006452611,0.00002303101,3.850639e-7,2.268477e-7,0.000002276435,0.008238669,0.9866163],"study_design_scores_gemma":[0.002403703,0.002571744,0.001902623,0.002153936,0.004045845,0.03990421,0.000006937391,0.000001691775,3.334801e-7,0.00003067392,0.9468219,0.0001563621],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001682513,0.9962144,0.00005376869,0.0003134723,0.0005663527,0.0009966997,0.0001293483,0.0000109592,0.00003249315],"genre_scores_gemma":[0.0011431,0.9969082,0.0005201524,0.0004083235,0.0004292726,0.0002676871,0.00001985375,0.00004211471,0.0002613172],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.98646,"threshold_uncertainty_score":0.8221727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1975848770","doi":"10.1016/j.eururo.2014.02.038","title":"Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review","year":2014,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Urology; Radiation therapy; Cystoscopy; Chemotherapy; Multimodal therapy; Surgery; Oncology; Cancer; Internal medicine; Urinary system","retraction":null,"screen_n_in":null,"score":{"opus":0.04263597856081241,"gpt":0.3543047655913776,"spread":0.3116687870305652,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000783072,0.000677027,0.007627784,0.0007919168,0.00003752852,0.00001439771,0.0003564025,0.0001858961,0.000596162],"category_scores_gemma":[0.0005067171,0.000425135,0.000995825,0.00134832,0.0002209399,0.00004034851,0.00007708641,0.0006377656,0.0001031396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001214755,"about_ca_system_score_gemma":0.0005575197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001414297,"about_ca_topic_score_gemma":0.00013537,"domain_scores_codex":[0.9945405,0.002170217,0.001588722,0.0008250367,0.000369759,0.0005058192],"domain_scores_gemma":[0.9970351,0.0008405593,0.0006746397,0.001056052,0.0002014677,0.0001921951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001397531,0.0004409547,0.0002311959,0.9131034,0.0200236,0.0008892951,0.0001822479,0.000007516303,9.836525e-7,0.00007872053,0.0003037352,0.06459858],"study_design_scores_gemma":[0.003662827,0.003601587,0.001323149,0.559666,0.2731777,0.0003873244,0.0000221993,0.00002625907,0.00000162858,0.000007062305,0.1570838,0.001040515],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004009647,0.9916018,0.00005556915,0.000196502,0.0001107346,0.00260435,0.00006276857,0.0000435177,0.005284642],"genre_scores_gemma":[0.002656276,0.9943056,0.00004502521,0.001994756,0.0001688466,0.000391864,0.0001059442,0.0001544303,0.0001772551],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3534375,"threshold_uncertainty_score":0.9998201,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135532181","doi":"10.1016/j.urolonc.2014.06.008","title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","year":2014,"lang":"en","type":"article","venue":"Urologic Oncology Seminars and Original Investigations","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":342,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Dipstick; Urinary system; Cytology; Urology; Prospective cohort study; Bladder cancer; Urine; Gastroenterology; Internal medicine; Urine cytology; Urinalysis; Cancer; Urinary bladder; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03112122500303147,"gpt":0.3306907502232353,"spread":0.2995695252202038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003050493,0.0001608162,0.000632156,0.000234808,0.0001055755,0.000003862573,0.00002763221,0.0001813621,0.00003820323],"category_scores_gemma":[0.00009148959,0.0001300209,0.00007230775,0.0002837114,0.001280976,0.00004221474,0.00003793429,0.0001072025,2.314021e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004313594,"about_ca_system_score_gemma":0.0001241841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000318246,"about_ca_topic_score_gemma":0.0001387518,"domain_scores_codex":[0.9989951,0.0001350167,0.0002570335,0.0003571266,0.00007598512,0.0001796942],"domain_scores_gemma":[0.9989769,0.0004636814,0.0001873447,0.0001409222,0.00009419549,0.0001369562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006545445,0.0003585252,0.9895463,0.0000697803,0.001517854,0.00001666668,0.0004508971,0.00002255669,0.002314243,0.003178288,0.0001824769,0.001687889],"study_design_scores_gemma":[0.003061596,0.01222968,0.9011788,0.00005413315,0.008007461,0.0003956734,0.0003799763,0.005942593,0.00324271,0.004964441,0.06029484,0.0002481058],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947701,0.001557696,0.0003541592,0.001578135,0.00005347595,0.0004777544,0.0001668002,0.00001582221,0.001026093],"genre_scores_gemma":[0.9860978,0.0004700021,0.01251525,0.0006472552,0.00005175862,0.0000842085,0.0000187988,0.00001005455,0.000104914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08836748,"threshold_uncertainty_score":0.5302098,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2792782785","doi":"10.1016/j.eururo.2018.02.014","title":"Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review","year":2018,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bladder cancer; Resection; Detrusor muscle; Cancer; Urology; Surgery; Internal medicine; Urinary bladder","retraction":null,"screen_n_in":null,"score":{"opus":0.04492470978304158,"gpt":0.3477794709534938,"spread":0.3028547611704522,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009972526,0.0006885412,0.00421777,0.0003492768,0.00006821739,0.00001632119,0.0003377173,0.0002877863,0.0004391895],"category_scores_gemma":[0.0003698531,0.0004957563,0.000779851,0.000566748,0.0001482801,0.00005258971,0.00007198392,0.000812566,0.001047813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003028531,"about_ca_system_score_gemma":0.0004964785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009852867,"about_ca_topic_score_gemma":0.0002209679,"domain_scores_codex":[0.9944118,0.002260599,0.001495831,0.0009664828,0.0003066045,0.0005586619],"domain_scores_gemma":[0.997815,0.0002187045,0.0005700687,0.001067595,0.0001354932,0.000193128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0000625479,0.0001212302,0.000008774674,0.9580708,0.0008824212,0.00114914,0.0001974763,1.057068e-7,6.639701e-7,0.000003565503,0.005294506,0.03420878],"study_design_scores_gemma":[0.001155597,0.00134867,0.00005993427,0.5694992,0.01405259,0.0008651285,0.000006889532,7.658419e-7,6.630504e-7,0.000004608419,0.4126169,0.0003889826],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000007690418,0.9804937,0.000009362908,0.0002852727,0.0007024648,0.005160899,0.00006507253,0.0000864484,0.01318915],"genre_scores_gemma":[0.0001048831,0.993899,0.00002077841,0.002168305,0.0008149031,0.0007337125,0.0001444723,0.0002138013,0.00190009],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4073224,"threshold_uncertainty_score":0.9997494,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2478136527","doi":"10.1016/j.eururo.2016.07.014","title":"Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","year":2016,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":318,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Systematic review; Urology; Urothelial carcinoma; Cochrane Library; Nephrectomy; Kidney cancer; MEDLINE; Bladder cancer; Meta-analysis; Surgery; Cancer; Kidney; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1337659355147479,"gpt":0.3754905467695089,"spread":0.241724611254761,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001453684,0.0009275631,0.005873781,0.0001925988,0.0001360638,0.00002110217,0.0006531649,0.0003213869,0.0003465321],"category_scores_gemma":[0.005900469,0.0004556152,0.002021388,0.0002333544,0.0003264897,0.00006054288,0.0001752647,0.0004999134,0.0001453546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002486662,"about_ca_system_score_gemma":0.002144686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001132993,"about_ca_topic_score_gemma":0.000008534143,"domain_scores_codex":[0.9939718,0.001656547,0.002357503,0.000869872,0.0004098335,0.000734408],"domain_scores_gemma":[0.9923939,0.004318534,0.001482674,0.001107368,0.0003083351,0.0003892031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004429392,0.0003845266,0.0004184716,0.6307964,0.004527496,0.0002962518,0.0001198768,1.468187e-7,0.00001281378,0.00001113966,0.2784344,0.08455559],"study_design_scores_gemma":[0.003176897,0.0008117575,0.0001583771,0.09784629,0.02017152,0.0002584273,0.00000951528,0.000001218227,0.000003852098,0.000002742559,0.8770903,0.0004691217],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005679217,0.985489,0.00005337957,0.003879408,0.001940506,0.006597088,0.0008226487,0.00006368429,0.001097536],"genre_scores_gemma":[0.0004865065,0.9850427,0.0000650998,0.01007956,0.001176954,0.001652637,0.000230522,0.0002423256,0.001023711],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5986559,"threshold_uncertainty_score":0.9997895,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2011595291","doi":"10.1371/journal.pone.0013821","title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":314,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Toronto General Hospital","funders":"","keywords":"HRAS; Neuroblastoma RAS viral oncogene homolog; KRAS; Medicine; Cancer research; Bladder cancer; Mutation; Cancer; Cystoscopy; Targeted therapy; Oncology; Cystectomy; Internal medicine; Gene; Biology; Urinary system; Colorectal cancer; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02830657857838668,"gpt":0.2781354505364668,"spread":0.2498288719580802,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000955733,0.0001491434,0.000260746,0.00007586637,0.00008369218,0.00002848437,0.00002945843,0.00008465086,0.00009232057],"category_scores_gemma":[0.00003354486,0.0001142528,0.00002317059,0.00008327321,0.0001370245,0.00006581497,0.00001554928,0.0001145764,0.000001308482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001440734,"about_ca_system_score_gemma":0.00008102114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008192073,"about_ca_topic_score_gemma":0.001067416,"domain_scores_codex":[0.9992762,0.00001844477,0.0001361152,0.0002723854,0.0001066566,0.0001901722],"domain_scores_gemma":[0.9995696,0.00008219841,0.00003910326,0.0001282132,0.00006494983,0.0001159662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001682874,0.001518873,0.5692682,0.0002294451,0.001927791,0.00001548441,0.002124313,3.980983e-7,0.3549794,0.00007496637,0.0002979748,0.06788031],"study_design_scores_gemma":[0.01400518,0.000947707,0.9367205,0.000159028,0.0002550544,0.00003518599,0.0003669178,0.0005093751,0.04409068,0.001372584,0.001182025,0.000355765],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911675,0.005155373,0.00001346384,0.002357016,0.00006428544,0.000817524,0.0001349759,0.000026417,0.0002634218],"genre_scores_gemma":[0.994497,0.003913767,0.0005310245,0.0003949707,0.000137671,0.0001932496,0.00003223519,0.00002699557,0.0002730666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3674523,"threshold_uncertainty_score":0.4659094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164589152","doi":"10.1200/jco.2005.05.516","title":"Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Lymphovascular invasion; Medicine; Cystectomy; Proportional hazards model; Lymph node; Urology; Internal medicine; Stage (stratigraphy); Bladder cancer; Oncology; Retrospective cohort study; Cancer; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.06142576127502575,"gpt":0.351058263771608,"spread":0.2896325024965822,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001408927,0.0002570901,0.001517004,0.0001216148,0.00007299905,0.00001952589,0.0001042072,0.0003675442,0.00007633091],"category_scores_gemma":[0.0005152347,0.0001567625,0.0001289115,0.0001815702,0.0006009417,0.0002039982,0.00007902227,0.0005842151,0.000003469883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008450568,"about_ca_system_score_gemma":0.0008824727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009292458,"about_ca_topic_score_gemma":0.0006014804,"domain_scores_codex":[0.9966046,0.0005983402,0.001279814,0.0003942968,0.0008096893,0.0003133172],"domain_scores_gemma":[0.9968377,0.001280259,0.0008712096,0.0001837666,0.0003664796,0.0004605796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01546537,0.002021322,0.9553369,0.00001926238,0.0006840787,0.0004335841,0.0002500916,0.000008179367,0.000004326027,0.00001846224,0.0001593098,0.02559906],"study_design_scores_gemma":[0.05765288,0.007954163,0.9309509,0.0004265583,0.0003562488,0.000115141,0.000111515,0.00005076744,0.00003129725,0.00005683084,0.002123057,0.0001706118],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968572,0.0008945676,0.0001389442,0.001245398,0.0002442319,0.0003254649,0.00001796638,0.000008103356,0.0002680821],"genre_scores_gemma":[0.9969735,0.001800339,0.0003833038,0.0005861601,0.0001549607,0.000005101903,0.00000888409,0.00002699509,0.00006079112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0421875,"threshold_uncertainty_score":0.6392589,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967513395","doi":"10.1093/jnci/93.8.597","title":"Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial","year":2001,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Dysuria; Mitomycin C; Confidence interval; Urology; Randomized controlled trial; Urine; Bladder cancer; Pharmacokinetics; Surgery; Chemotherapy; Regimen; Internal medicine; Urinary system; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.06299626001064262,"gpt":0.4401814813643143,"spread":0.3771852213536717,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001849923,0.000151595,0.001001357,0.0002210269,0.0000481937,0.000008281651,0.0002388845,0.00008084228,0.00006364152],"category_scores_gemma":[0.003040161,0.00008741611,0.0006160736,0.0004137141,0.0001937003,0.0001272209,0.0000400551,0.0002579681,0.000001031727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002999519,"about_ca_system_score_gemma":0.001497992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003094073,"about_ca_topic_score_gemma":0.00002372127,"domain_scores_codex":[0.9971331,0.0002220656,0.001348763,0.0001473117,0.001001428,0.0001473692],"domain_scores_gemma":[0.9971396,0.0004618424,0.0009876281,0.0001571931,0.001100325,0.0001533884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9471046,0.0009382773,0.00002342762,0.00002561336,0.001024092,0.00001088983,0.0005029973,0.0003132788,0.02482397,0.0002725068,0.00212776,0.02283253],"study_design_scores_gemma":[0.9042462,0.001214979,0.000535243,0.0002814213,0.0009092911,0.00009442399,0.00001609499,0.00009918278,0.0795519,0.0005094587,0.01245505,0.00008672568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770632,0.0007985915,0.003854054,0.006428779,0.005328356,0.00220793,0.0002056546,0.000008285489,0.00410516],"genre_scores_gemma":[0.9869329,0.0001854563,0.00928013,0.0006260797,0.002392353,0.00003816675,0.000003991157,0.00001308129,0.0005278335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05472793,"threshold_uncertainty_score":0.3639576,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2103725052","doi":"10.1016/j.eururo.2014.09.007","title":"Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer","year":2014,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia Hospital; Alberta Cancer Foundation; McGill University Health Centre; University of Alberta; McGill University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Bladder cancer; Cystectomy; Tolerability; Regimen; Neoadjuvant therapy; Internal medicine; Urology; Vinblastine; Gemcitabine; Oncology; Chemotherapy; Odds ratio; Surgery; Cancer; Adverse effect; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01883763667987342,"gpt":0.3187905982001069,"spread":0.2999529615202335,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001878921,0.0001626967,0.0003263835,0.00006134728,0.0000392449,0.000004857849,0.0001016777,0.00004487598,0.0004446973],"category_scores_gemma":[0.00004948479,0.0001291683,0.0001311301,0.00005005007,0.00008712525,0.00002487129,0.00002923472,0.0001026731,0.00002534378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003457534,"about_ca_system_score_gemma":0.00008319724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003984337,"about_ca_topic_score_gemma":0.00002043035,"domain_scores_codex":[0.9989232,0.0001395074,0.0002589301,0.0002997924,0.0001160551,0.0002625254],"domain_scores_gemma":[0.9992352,0.0001281681,0.0001211241,0.0002998128,0.0001182314,0.0000975209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.004208064,0.003587565,0.2512013,0.0007594566,0.003566811,0.0001523256,0.004074922,0.000346196,0.2005707,0.002446392,0.03585874,0.4932275],"study_design_scores_gemma":[0.01803617,0.004107297,0.7344164,0.00005170768,0.0005355315,0.00001759415,0.000046972,0.001293896,0.006929862,0.00009351726,0.2342199,0.0002512002],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8762476,0.000810559,0.01641129,0.01088235,0.001475953,0.002302449,0.0001420007,0.0001671803,0.09156059],"genre_scores_gemma":[0.988596,0.0001518704,0.001985189,0.007866424,0.0004494661,0.00005195293,0.00002478247,0.00006442976,0.0008098931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4929763,"threshold_uncertainty_score":0.5267332,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4290805456","doi":"10.1016/j.eururo.2022.07.002","title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors","year":2022,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":294,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Cancer Research UK; Francis Crick Institute; World Health Organization","keywords":"Medicine; Genitourinary system; Urinary system; Prostate cancer; Prostate; Epidemiology; Pathology; Terminology; Histopathology; Gynecology; Sex organ; Cancer; Urology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03257841791025608,"gpt":0.2827874383631029,"spread":0.2502090204528468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005878714,0.0002574241,0.000834942,0.0001275495,0.0002777996,0.00001028774,0.000199444,0.00003944871,0.0001365229],"category_scores_gemma":[0.00006934788,0.0001566421,0.00009726161,0.0005147072,0.0002448466,0.00002960253,0.0002231104,0.0003953358,0.000006188907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001163317,"about_ca_system_score_gemma":0.0004265204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001301747,"about_ca_topic_score_gemma":0.000002570506,"domain_scores_codex":[0.9971005,0.001355824,0.0007394861,0.0003784661,0.0002092474,0.0002165162],"domain_scores_gemma":[0.9983836,0.0001911864,0.000804536,0.0004813313,0.00005483155,0.00008446834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001220841,0.003454789,0.05102308,0.08165904,0.001996387,0.002006572,0.004753037,0.000004541054,0.00006175547,0.002546722,0.01381894,0.8374543],"study_design_scores_gemma":[0.0007883754,0.002598131,0.05318796,0.001168935,0.0009324922,0.008522299,0.0002983651,0.000004591272,0.000002241344,0.000003768173,0.9323192,0.0001737052],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005836007,0.9864097,0.000001942863,0.0004734659,0.0002682483,0.001785098,0.0001731624,0.00003593431,0.005016453],"genre_scores_gemma":[0.08481273,0.910656,0.000009376697,0.0001358921,0.0001423666,0.00004603647,0.0001943965,0.0001263395,0.00387687],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9185002,"threshold_uncertainty_score":0.6387679,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2609464379","doi":"10.1016/j.eururo.2017.04.015","title":"Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review","year":2017,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University Medical Centre","funders":"","keywords":"Medicine; Grading (engineering); Bladder cancer; Reproducibility; Disease; Repeatability; Oncology; Cancer; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1039229570986822,"gpt":0.3529945489161886,"spread":0.2490715918175065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004755809,0.0005810155,0.003222207,0.0003048873,0.000207233,0.00003157157,0.0004473075,0.0001719406,0.00001854879],"category_scores_gemma":[0.0067149,0.0003983567,0.0001864198,0.0006471747,0.0002444386,0.0001250956,0.0002491734,0.0005391226,0.00001393947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004537292,"about_ca_system_score_gemma":0.001325672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000667624,"about_ca_topic_score_gemma":0.0005759871,"domain_scores_codex":[0.9917424,0.003399722,0.002600285,0.001422115,0.0003710085,0.0004644872],"domain_scores_gemma":[0.9915074,0.0005803666,0.004933188,0.001953113,0.0008826048,0.0001433979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00004215011,0.0002630087,0.04768779,0.8591735,0.001384418,0.00003108751,0.001125425,0.00002305355,0.00005617847,0.00001365868,0.004355131,0.08584456],"study_design_scores_gemma":[0.003174799,0.001367084,0.3854506,0.5405928,0.01755063,0.0002623255,0.000113121,0.0001559288,0.000009184219,0.000007890683,0.05031348,0.001002199],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002993034,0.9865416,0.00001055379,0.001803471,0.0007260297,0.007264711,0.0001528869,0.00003249765,0.0004752639],"genre_scores_gemma":[0.09967034,0.8981062,0.00001381581,0.0007531421,0.0003074595,0.000269039,0.00009762163,0.0001334133,0.0006489955],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3377628,"threshold_uncertainty_score":0.9998468,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985060557","doi":"10.1046/j.1523-5394.2002.106011.x","title":"Bladder Cancer","year":2002,"lang":"en","type":"review","venue":"Cancer Practice","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Bladder cancer; Cancer; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.128576035822915,"gpt":0.4535409379707624,"spread":0.3249649021478473,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000134335,0.0006591145,0.001976833,0.0001615106,0.0001123589,0.00005976326,0.0002122656,0.0004557125,0.010272],"category_scores_gemma":[0.0001868745,0.0004969873,0.0006004884,0.000529096,0.00008014093,0.0002949454,0.00006699844,0.0009319758,0.001136298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006568,"about_ca_system_score_gemma":0.001747284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009954486,"about_ca_topic_score_gemma":0.0000320572,"domain_scores_codex":[0.9974673,0.000174693,0.0005741219,0.0007657756,0.0005019435,0.0005162045],"domain_scores_gemma":[0.9978161,0.0003116701,0.0005565334,0.0007453205,0.0002476313,0.0003226796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000468117,0.0002039987,0.000005016082,0.007365762,0.002320542,0.0002221909,0.00007936585,2.642322e-7,1.311293e-7,0.00002255071,0.0593894,0.930344],"study_design_scores_gemma":[0.0008380872,0.0001252206,0.000003037828,0.01073947,0.02015226,0.0004399336,0.00002138389,0.000001519093,0.000001890307,0.000003554924,0.9672387,0.0004349838],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[1.436702e-7,0.933412,0.000007570189,0.001248382,0.001466368,0.001412122,0.0002572716,0.0001221318,0.06207398],"genre_scores_gemma":[0.000001067371,0.9601608,0.00021511,0.002636286,0.002440739,0.002077119,0.00005990376,0.0001917772,0.0322172],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.929909,"threshold_uncertainty_score":0.9997482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1969979201","doi":"10.1016/j.eururo.2015.01.032","title":"Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature","year":2015,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Cystectomy; Predictive modelling; Disease; Risk assessment; MEDLINE; Intensive care medicine; Oncology; Cancer; Internal medicine; Machine learning; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.06722718343894528,"gpt":0.3468141931814235,"spread":0.2795870097424782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000207275,0.0002880565,0.001324721,0.00009258315,0.00002046281,0.000008681246,0.0001394601,0.0001254474,0.00004442324],"category_scores_gemma":[0.0001606358,0.0001634036,0.0001855427,0.0003580412,0.0001207982,0.00003125306,0.0001215559,0.0005188605,0.00001620593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005881826,"about_ca_system_score_gemma":0.0003322492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007536657,"about_ca_topic_score_gemma":0.000002532367,"domain_scores_codex":[0.9979022,0.0008834324,0.0005199188,0.0003506986,0.0001610135,0.0001827652],"domain_scores_gemma":[0.9990008,0.0001000637,0.0002726385,0.0003924992,0.0001550437,0.00007894626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003969995,0.00008375355,0.0006122014,0.1012084,0.0003269539,0.0001621631,0.0002049373,1.63184e-7,4.272609e-7,0.00001121122,0.007503872,0.8898462],"study_design_scores_gemma":[0.0005656591,0.000320761,0.00305473,0.08424429,0.002255832,0.0004439702,0.000002309799,3.677532e-7,8.631744e-8,0.000005172592,0.90902,0.00008683098],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003087916,0.993279,3.110387e-7,0.0003335351,0.0003174989,0.002023949,0.0004156674,0.00001905136,0.003580143],"genre_scores_gemma":[0.00004984722,0.9975281,0.00001019884,0.001583689,0.0002371021,0.0001014923,0.0001733025,0.00005215032,0.0002640922],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9015161,"threshold_uncertainty_score":0.6663404,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133646931","doi":"10.1016/j.eururo.2012.09.057","title":"ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers","year":2012,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cystoscopy; Bladder cancer; Urine cytology; MEDLINE; Cancer; Gold standard (test); Urinary system; Oncology; Internal medicine; Urology","retraction":null,"screen_n_in":null,"score":{"opus":0.05054170174184221,"gpt":0.3471694749275516,"spread":0.2966277731857094,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002118169,0.0004169666,0.0007866465,0.000217928,0.00005405679,0.00002249929,0.0001541877,0.0001686344,0.001427526],"category_scores_gemma":[0.00006841095,0.0003327841,0.0001997643,0.0001024452,0.0001350141,0.00005896134,0.00009610524,0.000428203,0.0004053151],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000741055,"about_ca_system_score_gemma":0.00009739156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004437205,"about_ca_topic_score_gemma":0.000006967998,"domain_scores_codex":[0.9980769,0.0004646272,0.000391523,0.0005123401,0.0002201445,0.0003344406],"domain_scores_gemma":[0.9989994,0.000182107,0.0002468018,0.0002894439,0.00007250325,0.0002097664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001365279,0.0001253094,0.0004693055,0.0005480767,0.00131165,0.0002630125,0.00006469769,7.630823e-7,8.488104e-7,0.0001162982,0.008589018,0.9883745],"study_design_scores_gemma":[0.001276553,0.000356688,0.001549667,0.0008321693,0.002976072,0.0001749267,0.000004467011,0.000001774921,0.000002072869,0.000003016872,0.9925827,0.0002398358],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003915518,0.9602073,0.0000723605,0.000655247,0.0008297837,0.0007622252,0.0001585709,0.00005831218,0.03721709],"genre_scores_gemma":[0.0006498218,0.9932767,0.0001283803,0.002760894,0.0007327651,0.0001975815,0.0003938487,0.0001326245,0.001727448],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9881347,"threshold_uncertainty_score":0.9999124,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3088359032","doi":"10.1016/j.eururo.2020.09.006","title":"Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita","year":2020,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bladder cancer; Gross domestic product; Per capita; Incidence (geometry); Demography; Mortality rate; Cancer; Environmental health; Population; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04096937007477142,"gpt":0.3056264929394119,"spread":0.2646571228646404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008564318,0.0001415309,0.0002626888,0.00002675119,0.00005502623,0.00001994102,0.00004130611,0.00002584345,0.00006373743],"category_scores_gemma":[0.00007570139,0.00009810641,0.0000178121,0.000100873,0.0002317072,0.00008682484,0.00008860195,0.0000847348,0.000003151756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001960293,"about_ca_system_score_gemma":0.00005805357,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005020815,"about_ca_topic_score_gemma":0.0004352118,"domain_scores_codex":[0.999154,0.0001161349,0.0001458119,0.0003257709,0.00008791307,0.0001703355],"domain_scores_gemma":[0.9995317,0.00005156787,0.00007377381,0.0001391547,0.00006556121,0.0001381747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001551861,0.00004275073,0.9940126,0.00001962274,0.0002585741,0.00006288038,0.001417769,0.000005255554,0.0002996362,0.00007146509,0.0003626392,0.0032916],"study_design_scores_gemma":[0.001340857,0.0007562874,0.9966049,0.000007059914,0.0003055088,0.0001175936,0.00005156685,0.00002192065,0.00002736831,0.00002366954,0.0006574695,0.00008579125],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928119,0.002442115,0.00002061738,0.003089173,0.00003808823,0.0001454701,0.0001809871,0.00002603017,0.001245588],"genre_scores_gemma":[0.9976347,0.0003005045,0.00005983378,0.001756963,0.0001239374,0.000005611902,0.00001248109,0.00001775384,0.00008818561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004822797,"threshold_uncertainty_score":0.4000663,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142088661","doi":"10.1158/1078-0432.ccr-06-0372","title":"Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":262,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nomogram; Cystectomy; Bladder cancer; Lymphovascular invasion; Urology; Lymphadenectomy; Proportional hazards model; Radiation therapy; Stage (stratigraphy); AJCC staging system; Carcinoma in situ; Lymph node; Surgery; Cancer; Oncology; Internal medicine; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.1471153862886078,"gpt":0.4994884676199847,"spread":0.3523730813313769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002353716,0.0002340105,0.0006139862,0.0001241514,0.0002191595,0.00008637006,0.000249421,0.0002987415,0.000477301],"category_scores_gemma":[0.001553623,0.0001802207,0.0004020765,0.0004002548,0.0005525812,0.0001223447,0.0001423517,0.0009962565,0.00004622796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003114336,"about_ca_system_score_gemma":0.001226066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003924503,"about_ca_topic_score_gemma":0.001068752,"domain_scores_codex":[0.9961862,0.0003085264,0.0008614265,0.0008144061,0.0008310835,0.0009983542],"domain_scores_gemma":[0.9962496,0.002052922,0.0001015954,0.000560235,0.0005947311,0.0004408835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01962201,0.002056581,0.8094527,0.0007808434,0.0004818263,0.0001711126,0.0001342847,0.000002738636,0.001788756,0.0001119705,0.01400202,0.1513952],"study_design_scores_gemma":[0.03569177,0.006633271,0.4930033,0.0007271988,0.0005136774,0.0000335671,0.0001690661,0.001541048,0.004072478,0.001702819,0.4552539,0.0006579724],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800597,0.002865988,0.0005419917,0.005735564,0.001186044,0.004982321,0.0002298371,0.0001979557,0.004200639],"genre_scores_gemma":[0.9854672,0.000184454,0.0008583398,0.0003970313,0.004969086,0.003353514,0.00005741484,0.00008278719,0.00463015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4412518,"threshold_uncertainty_score":0.7349186,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2124163052","doi":"10.1016/j.eururo.2012.04.052","title":"Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma","year":2012,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Cuff; Urology; Ureter; Concomitant; Bladder cancer; Stage (stratigraphy); Retrospective cohort study; Upper urinary tract; Surgery; Carcinoma; Urinary system; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02826661581038656,"gpt":0.3275261250870283,"spread":0.2992595092766418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002782044,0.0002750985,0.0004958579,0.0001321565,0.00006229566,0.000008016792,0.0001352192,0.00007917406,0.0002595193],"category_scores_gemma":[0.00005195675,0.0001846024,0.0007198292,0.0000676397,0.0000861353,0.00006213874,0.00005290249,0.0001775764,0.00008896252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001188287,"about_ca_system_score_gemma":0.00003827331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001608955,"about_ca_topic_score_gemma":4.053737e-7,"domain_scores_codex":[0.9984165,0.0002205204,0.0003246997,0.0002979814,0.0001877969,0.0005524806],"domain_scores_gemma":[0.9991815,0.0001574277,0.00009657694,0.0003297019,0.00002017226,0.0002146315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001782741,0.001047531,0.9871894,0.00003474974,0.0008200936,0.0002217257,0.0003871334,0.000003073128,0.0008384307,0.0002057697,0.001769693,0.005699651],"study_design_scores_gemma":[0.007012106,0.005546499,0.9701635,0.000009623789,0.0006087033,0.00006024961,0.00001666494,0.000006641253,0.0001664829,0.00001969677,0.0162336,0.0001562924],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698067,0.0001683362,0.0002515597,0.0003595933,0.0007454518,0.0008469218,0.00006088132,0.00005441082,0.02770619],"genre_scores_gemma":[0.9965817,0.000005025339,0.000572536,0.001527002,0.0005012776,0.00003982543,0.0000525424,0.00006991009,0.0006501719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02705602,"threshold_uncertainty_score":0.7527866,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138662111","doi":"10.1016/j.canep.2013.02.002","title":"Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis","year":2013,"lang":"en","type":"article","venue":"Cancer Epidemiology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé","keywords":"Medicine; Incidence (geometry); Demography; Stage (stratigraphy); Epidemiology; Mortality rate; Cancer; Bladder cancer; Proportional hazards model; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1053071801249395,"gpt":0.4100337642303641,"spread":0.3047265841054246,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005636023,0.0002539344,0.001305302,0.0005028387,0.00003628834,0.000005606514,0.0001003921,0.0001666194,0.0034575],"category_scores_gemma":[0.0001158249,0.0001965257,0.0001437488,0.001142366,0.0003732542,0.00009713099,0.00004834037,0.0002255858,0.000006966686],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001872186,"about_ca_system_score_gemma":0.00015028,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.07485341,"about_ca_topic_score_gemma":0.01901573,"domain_scores_codex":[0.9976931,0.0004257303,0.0007630976,0.0005252417,0.0001333076,0.0004595379],"domain_scores_gemma":[0.9983632,0.0006261094,0.0002722771,0.000378034,0.0001531658,0.0002071926],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001440345,0.00008211581,0.991896,0.00009415492,0.001497865,0.000009904366,0.0004113977,0.001571066,0.0001556893,0.0002160138,0.001100478,0.002821283],"study_design_scores_gemma":[0.00156166,0.0001464684,0.9910052,0.0000767976,0.0006584432,0.00000114444,0.0004357753,0.002820608,0.0001976042,0.0008339121,0.002096665,0.0001657205],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980992,0.01566564,0.0001440128,0.00175417,0.0002230728,0.0004606002,0.0003880389,0.00002443363,0.0003480962],"genre_scores_gemma":[0.9810617,0.01628891,0.0001496027,0.001020216,0.0001124135,0.0004091343,0.0001985176,0.0000221256,0.0007373966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05583767,"threshold_uncertainty_score":0.9988847,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2042134048","doi":"10.1007/s00345-011-0709-9","title":"Impact of gender on bladder cancer incidence, staging, and prognosis","year":2011,"lang":"en","type":"review","venue":"World Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nephrology; Incidence (geometry); Internal medicine; Bladder cancer; Oncology; Cancer; Hepatology; Urology; Gynecology","retraction":null,"screen_n_in":null,"score":{"opus":0.08057512370437199,"gpt":0.3952017661553585,"spread":0.3146266424509865,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002167811,0.0003542917,0.002039083,0.0007536504,0.00002690731,0.000006533309,0.000151404,0.0001836892,0.001813981],"category_scores_gemma":[0.00003554343,0.0002115312,0.0006676199,0.0002688738,0.000144658,0.00005111982,0.00004316158,0.0006782194,0.000008066856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001730691,"about_ca_system_score_gemma":0.001072157,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001067932,"about_ca_topic_score_gemma":0.00002917569,"domain_scores_codex":[0.9983284,0.0001526745,0.000793101,0.0002280496,0.0002195624,0.0002782283],"domain_scores_gemma":[0.9981887,0.0001118676,0.001063552,0.0002158875,0.000201874,0.000218076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005274306,0.0004063121,0.04599624,0.002249717,0.005183013,0.0002484811,0.0002168497,9.580459e-7,0.0000010672,0.00006345127,0.005613937,0.9394925],"study_design_scores_gemma":[0.001809618,0.004442774,0.02366662,0.003125898,0.009578614,0.001307969,0.000005165679,5.092931e-7,0.000001762332,0.0001159988,0.9557145,0.0002305779],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007451957,0.99527,0.0000033005,0.00006406727,0.0002597305,0.000402422,0.00003722961,0.000005692413,0.003212356],"genre_scores_gemma":[0.01098818,0.9877253,0.00008319766,0.0002206933,0.0003803587,0.00002433337,0.000004030572,0.00005109888,0.0005227822],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9501005,"threshold_uncertainty_score":0.9990985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4376272229","doi":"10.1016/s1470-2045(23)00170-5","title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; University of Toronto; University Health Network; Mount Sinai Hospital","funders":"","keywords":"Cystectomy; Medicine; Propensity score matching; Bladder cancer; Urology; Retrospective cohort study; Stage (stratigraphy); Clinical endpoint; Surgery; Cancer; Internal medicine; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.1688769722248086,"gpt":0.3886908834160771,"spread":0.2198139111912685,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004527216,0.0002012872,0.0008733657,0.0001128693,0.0002579025,0.00001536362,0.0001398894,0.0001596655,0.0001177384],"category_scores_gemma":[0.00008957649,0.0001151194,0.0001945954,0.0006239624,0.0003762661,0.00004296371,0.00005534932,0.0002034149,0.00001633598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002543745,"about_ca_system_score_gemma":0.0008907254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007839921,"about_ca_topic_score_gemma":0.00149303,"domain_scores_codex":[0.9986141,0.0001791865,0.0002292644,0.000390961,0.0001948016,0.000391645],"domain_scores_gemma":[0.998893,0.0004200116,0.0001018324,0.0003310661,0.0001293816,0.0001247191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.13313,0.003897207,0.5454572,0.0009314583,0.05144009,0.001077462,0.01072111,0.0002830504,0.02546654,0.006127319,0.02371228,0.1977563],"study_design_scores_gemma":[0.06456873,0.001916243,0.8987486,0.00004204942,0.003785895,0.00003586325,0.0001928179,0.002043011,0.002298385,0.0004312765,0.0256571,0.0002799742],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844909,0.0006435619,0.0005198093,0.0115587,0.000380658,0.001644821,0.0002424132,0.0001552606,0.0003638431],"genre_scores_gemma":[0.9944121,0.001702019,0.0005991618,0.001443775,0.000677242,0.0007271178,0.0001595435,0.00001887903,0.000260135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3532914,"threshold_uncertainty_score":0.4694432,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2972475028","doi":"10.1016/j.euf.2019.09.003","title":"What Is the Significance of Variant Histology in Urothelial Carcinoma?","year":2019,"lang":"en","type":"review","venue":"European Urology Focus","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Cystectomy; Lymph node; Carcinoma; Chemotherapy; Radiation therapy; Oncology; Adenocarcinoma; Stage (stratigraphy); Internal medicine; Pathology; Bladder cancer; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04842911189873227,"gpt":0.3105415743893578,"spread":0.2621124624906255,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004860388,0.0005047555,0.002133213,0.0002490118,0.00004130113,0.00001484227,0.0005319736,0.0002759207,0.0003868446],"category_scores_gemma":[0.00004857326,0.000316421,0.0005455731,0.0002878363,0.0003443695,0.00005714071,0.0001551366,0.0008083415,0.0009077863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001353865,"about_ca_system_score_gemma":0.0006391035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001535428,"about_ca_topic_score_gemma":0.00001936741,"domain_scores_codex":[0.9964081,0.001305192,0.0008829641,0.000733046,0.0002043098,0.0004663806],"domain_scores_gemma":[0.9979041,0.0003216309,0.0004746612,0.001152516,0.0000565358,0.00009054637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003009355,0.0002795684,0.0002140305,0.003972002,0.0005385633,0.002023637,0.0007965449,6.398021e-7,0.000005282195,0.0003825247,0.00264036,0.9888459],"study_design_scores_gemma":[0.001440796,0.0008976734,0.0004053756,0.0009045175,0.002091706,0.000770216,0.00002000036,0.000001471361,0.000005595588,0.0000470108,0.9931898,0.0002258818],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004779581,0.9764432,0.00001382834,0.0009134204,0.001507296,0.001939403,0.00007281263,0.0000265621,0.01903569],"genre_scores_gemma":[0.005275652,0.9899619,0.00002168426,0.001156335,0.0003673194,0.00008462821,0.0000306348,0.000141875,0.002960029],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9905494,"threshold_uncertainty_score":0.9999288,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2124017956","doi":"10.1016/j.eururo.2010.02.024","title":"Prevention and Management of Complications Following Radical Cystectomy for Bladder Cancer","year":2010,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cystectomy; Bladder cancer; Quality of life (healthcare); MEDLINE; Sexual function; Intensive care medicine; General surgery; Surgery; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05861563086777336,"gpt":0.3833460492484744,"spread":0.324730418380701,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001666193,0.0002146634,0.0008107729,0.0000989218,0.00005414028,0.000005730379,0.0001081961,0.0001140001,0.00004869015],"category_scores_gemma":[0.000009962302,0.0001706489,0.000350062,0.00008469672,0.00008553049,0.00001547827,0.00006738972,0.0002073253,0.00001980739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002481365,"about_ca_system_score_gemma":0.00007651091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005474005,"about_ca_topic_score_gemma":0.00000390487,"domain_scores_codex":[0.9988426,0.0001390512,0.0003918024,0.0003587635,0.00008797226,0.0001798279],"domain_scores_gemma":[0.9993191,0.00006439218,0.0001890007,0.000316492,0.00002825958,0.00008271397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002921166,0.0001114638,0.00002735349,0.0061113,0.001238329,0.00003264353,0.0000220583,6.707748e-8,0.000003237902,0.0003970572,0.0005425725,0.9914847],"study_design_scores_gemma":[0.001506182,0.0003211365,0.0004900594,0.001531568,0.006140365,0.00007272609,0.000002278126,0.000001719709,7.945061e-7,0.00003405781,0.9897885,0.0001106524],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004734698,0.9860961,0.0006478359,0.0001658411,0.0003038429,0.002046318,0.00006516169,0.00003367873,0.01059387],"genre_scores_gemma":[0.0002826435,0.9960852,0.001377913,0.0001456524,0.0001776641,0.0003928673,0.0001579722,0.00007540358,0.001304649],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9913741,"threshold_uncertainty_score":0.6958859,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}